Paul K. Audhya Sells 2,394 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,394 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $10.02, for a total transaction of $23,987.88. Following the transaction, the insider now owns 102,940 shares of the company’s stock, valued at approximately $1,031,458.80. The trade was a 2.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

KalVista Pharmaceuticals Stock Up 1.0 %

NASDAQ:KALV opened at $10.88 on Thursday. The company has a market capitalization of $537.77 million, a PE ratio of -2.99 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50. The stock’s 50 day moving average price is $8.98 and its 200 day moving average price is $10.35.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. As a group, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KALV has been the subject of a number of recent analyst reports. JMP Securities assumed coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target for the company. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Bank of America began coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $23.80.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in KALV. Aquatic Capital Management LLC purchased a new stake in KalVista Pharmaceuticals during the 4th quarter valued at approximately $44,000. Tower Research Capital LLC TRC raised its stake in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 5,502 shares during the last quarter. Legal & General Group Plc raised its stake in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 1,494 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares during the last quarter. Finally, Martin Worley Group purchased a new position in KalVista Pharmaceuticals in the 4th quarter valued at $86,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).